论文部分内容阅读
目的观察布地奈德合并博利康尼雾化吸入治疗支原体肺炎疗效。方法选择本院符合肺炎支原体肺炎诊断标准的患儿100例,随机分成2组,均行常规治疗,包括吸氧、祛痰、止咳、抗感染、阿奇霉素抗支原体等综合治疗,治疗组在对照组基础上加用吸入用布地奈德混悬液1mg和博利康尼雾化液5 mg联合雾化吸入,每天2~3次。结果治疗组总有效例数48例(96%),对照组总有效例数42例(84%)。结论布地奈德合并博利康尼雾化吸入治疗支原体肺炎疗效好,不良反应小,使用方便。
Objective To observe the curative effect of Budesonide combined with Boli Kang Ni inhalation therapy in mycoplasma pneumonia. Methods A total of 100 children with mycoplasma pneumoniae pneumonia were enrolled in this study. They were randomly divided into 2 groups. All patients were treated with conventional therapy, including oxygen, expectorant, cough, anti-infection and anti-mycoplasma azithromycin. On the basis of inhalation with budesonide suspension 1mg and Boli Kang Ni aerosol 5mg inhalation, 2 or 3 times a day. Results The total effective number of cases in treatment group was 48 cases (96%), and the control group of 42 cases (84%). Conclusions Budesonide combined with Boli Kang Ni inhalation therapy for mycoplasma pneumonia has good curative effect, small adverse reactions and easy to use.